Bolt Biotherapeutics
BOLT
37 hedge funds and large institutions have $9.99M invested in Bolt Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
16% more funds holding
Funds holding: 32 → 37 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 2.45% → 2.44% (-0.02%)
18% less capital invested
Capital invested by funds: $12.2M → $9.99M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.7K |
| 2 |
EGM
Engineers Gate Manager
New York
|
+$43.8K |
| 3 |
Goldman Sachs
New York
|
+$30.2K |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$30.2K |
| 5 |
Squarepoint
New York
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$324K |
| 2 |
NM
Newtyn Management
New York
|
-$304K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95.9K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$38.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$16.5K |
BOLT Hedge Fund Activity: Q4 2024 in Review
37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2024, worth a combined $9.99M — down 18% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BOLT positions and 5 closed out — a net gain of 5 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $47.7K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $324K sold.
- 37 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2024, up from 32 in Q3 2024.
- Funds reported $9.99M of Bolt Biotherapeutics stock for Q4 2024, down 18% quarter-over-quarter.
- 10 funds opened new Bolt Biotherapeutics positions in Q4 2024 and 5 closed out, a net change of +5 holders.
- The largest Bolt Biotherapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $47.7K added.
- The largest Bolt Biotherapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $324K sold.
Based on aggregated 13F filings for Q4 2024.